Riboflavin is one of 143 small molecule programs targeting Keratoconus, Unstable. It is currently in Phase 1.
Indications
Total Trials
Active Trials
Competitors
Pipeline
Competition
172 competitors in Chronic Kidney Disease
Epogen
Riboflavin
Uloric
Sovaldi
Glucotrol
Vemlidy
Lorelco
Flomax
Activase
Januvia
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Clinical
Sources
Details